Definitions and outcome measures of clinical trials regarding opioid-induced constipation: A systematic review

Journal of Clinical Gastroenterology

Volumn 49, Issue 1, 2015, Pages 9-16

  Gaertner, Jan ^a   Siemens, Waldemar ^a   Camilleri, Michael ^b   Davies, Andrew ^c   Drossman, Douglas A ^d   Webster, Lynn R ^e   Becker, Gerhild ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e American Academy of Pain Medicine   (United States)

Author keywords

Bowel dysfunction; Burden; Diagnosis; Opiate

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONSTIPATION; EMBASE; HUMAN; MEDLINE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PUBLICATION; REVIEW; STANDARD; SYSTEMATIC REVIEW; WEB OF SCIENCE; CHEMICALLY INDUCED; NOMENCLATURE;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; CONSTIPATION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); TERMINOLOGY AS TOPIC;

EID: 84908165264     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000246     Document Type: Review

References (71)

1. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847-1865.
2. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206.
3. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(suppl): 11S-18S.
4. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42.
5. Hjalte F, Berggren A, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage. 2010;40:696-703.
6. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93:247-257.
7. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181-1187.
8. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
9. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
10. Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions. 2011. Available at: http://handbook.cochrane.org/. Accessed September 18, 2013.
11. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011;65:472-478.
12. Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011;14:177-183.
13. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428-440.
14. Joswick T, Mareya SM, Lichtlen P, et al. Time to onset of lubiprostone treatment effect in chronic non-cancer pain patients with opioid-induced constipation: data from two phase 3, randomized, double-blind, placebo-controlled trials. Gastroenterology. 2013;144(suppl 1):540.
15. Lichtlen P, Joswick T, Woldegeorgis F, et al. Lubiprostone is well tolerated in chronic non-cancer pain patients with opioid-induced constipation in three phase 3, randomized, double-blind, placebo-controlled trials. Gastroenterology. 2013;144(suppl 1):916.
16. Mareya SM, Lichtlen P, Woldegeorgis F, et al. Lubiprostone improves complete spontaneous bowel movement frequency in chronic non-cancer pain patients with opioid-induced constipation. Gastroenterology. 2013;144(suppl 1):539-540.
17. Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7:67-72.
18. Wirz S, Nadstawek J, Elsen C, et al. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium pico-sulphate and lactulose. Eur J Cancer Care. 2012;21:131-140.
19. McShane RE, McLane AM. Constipation. Consensual and empirical validation. Nurs Clin North Am. 1985;20:801-808.
20. Bruera E, Suarez-Almazor M, Velasco A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage. 1994;9:515-519.
21. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737-743.
22. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;1: CD003448.
23. McMillan SC, Williams FA. Validity and reliability of the Constipation Assessment Scale. Cancer Nurs. 1989;12:183-188.
24. Norton C. The causes and nursing management of constipation. Br J Nurs. 1996;5:1252-1258.
25. Ross H. Constipation: cause and control in an acute hospital setting. British Journal of Nursing. 1998;7:13.
26. Winney J. Constipation. Primary Health Care. 1998;8:31-36.
27. Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12:175-184.
28. Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12:185-193.
29. Ishihara M, Iihara H, Okayasu S, et al. Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. Support Care Cancer. 2010;18:1531-1538.
30. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrex-one treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38:683-690.
31. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
32. Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am. 1987;71:303-311.
33. Portenoy RK, Thomas J, Moehl BML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35:458-468.
34. Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer. 2008;16:999-1009.
35. Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912-2921.
36. Etropolski M, Kelly K, Okamoto A, et al. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28:401-417.
37. Loewenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531-543.
38. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503-3512.
39. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343.
40. Twycross RG, McNamara P, Schuijt C, et al. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med. 2006;20:419-423.
41. Liu MW, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48-53.
42. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use - a randomized controlled trial. JAMA. 2000;283:367-372.
43. Yuan CS, Foss JF, O'Connor M, et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999;83:631-635.
44. Ramesh PR, Kumar KS, Rajagopal MR, et al. Managing morphine-induced constipation: a controlled comparison of an Ayurvedic formulation and senna. J Pain Symptom Manage. 1998;16:240-244.
45. Sykes NP. A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage. 1996;11:363-369.
46. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135-144.
47. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554-562.
48. Jamal MM, Mareya SM, Woldegeorgis F, et al. Lubiprostone significantly improves treatment response in non-methadone opioid-nduced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3 randomized double-blind placebo-controlled clinical trial. Gastroenterology. 2012;142:144-145.
49. Singla NK, Techner LM, Gabriel K, et al. CB-5945 0.25 mg twice daily is associated with significantly increased spontaneous bowel movement and greater proportion of responders compared with placebo in patients on chronic opioid therapy for noncancer pain (45CL242; NCT01207427). Gastroenterology. 2012;143:26-27.
50. Webster L, Michna E, Khan A, et al. The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain. J Pain. 2011;12:P70.
51. Webster LR, Blonsky ER, Matz P, et al. Once daily oral NKTR-118 normalizes gastrointestinal function in patients with opioid-induced constipation without reversing analgesia: results of a randomized, double-blind, placebo-controlled phase 2 study. Pain Med. 2010;11:322.
52. Mercadante S, Ferrera P, Casuccio A. Effectiveness and tolerability of amidotrizoate for the treatment of constipation resistant to laxatives in advanced cancer patients. J Pain Symptom Manage. 2011;41:421-425.
53. Moss J, Dickerson D, Nunnally M, et al. Methylnaltrexone treats opioid-induced bowel dysfunction in three critically ill patients. Am J Gastroenterol. 2011;106:369.
54. Sawh SB, Danga A, Selveraj IP, et al. Use of methyl-naltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc. 2010;14(suppl 1):S163.
55. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39-46.
56. Duerden M, Schulman S, Tzanis E, et al. Efficacy of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in subgroups of patients with chronic, nonmalignant pain. J Gen Intern Med. 2010;25:267-268.
57. Blonsky R, Michna E, Schulman S, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain. J Pain. 2009;10:S52.
58. Latasch L, Zimmermann M, Eberhardt B, et al. Oral naloxone antagonizes morphine-induced constipation. Anaesthesist. 1997;46:191-194.
59. Netzer P, Sendensky A, Wissmeyer MP, et al. The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: a placebo-controlled double-blinded crossover preclinical volunteer study. Aliment Pharmacol Ther. 2008;28:1334-1341.
60. Freye E, Rosenkranz B, Neruda B. Constipation after tilidine/naloxone and tramadol in comparison to codeine. A dose response study in human volunteers. Schmerz. 1996;10:254-260.
61. Clemens K, Quednau I, Klaschik E. Analgesic efficacy and improved bowel function during a pain therapy with a combination of oxycodone/naloxone prolonged-release tablets in geriatric patients. Pain Pract. 2009;9:136.
62. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50-60.
63. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64:763-774.
64. Meissner W, Leyendecker P, Mueller Lissner S, et al. A randomised controlled trial with prolonged-release oral oxy-codone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56-64.
65. Peppin J, Pappagallo M, Barrett A, et al. Effect of subcutaneous methylnaltrexone on patient-reported outcomes in advanced illness patients with opioid-induced constipation. J Pain. 2013;14:S62.
66. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007;34:547-565.
67. Camilleri M, Rothman M, Ho KF, et al. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol. 2011;106:497-506.
68. Clark K, Currow DC. Constipation in palliative care: what do we use as definitions and outcome measures? J Pain Symptom Manage. 2013;45:753-762.
69. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22:1-17.
70. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
71. Guyatt GH, Ferrans CE, Halyard MY, et al. Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc. 2007;82:1229-1239.